Carey Kernodle Anders
Professor of Medicine
Current Research Interests
Breast Cancer
Triple Negative Breast Cancer
Brain Metastases
Young women and Breast Cancer
Current Appointments & Affiliations
-
Education, Training, & Certifications
-
-
Leadership & Clinical Positions at Duke
-
Medical Director of the Brain and Spine Metastases Program, Duke Cancer Institute
-
-
Selected Grants
-
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with
HER2-p
awarded by AstraZeneca Pharmaceuticals, LP
2022 - 2027
-
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRa overexpressing tumors
awarded by Elucida Oncology, Inc
2022 - 2027
-
Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physicians
awarded by Hoosier Cancer Research Network, Inc
2022 - 2027
-
A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
awarded by Pfizer, Inc.
2020 - 2025
-
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Br
awarded by AstraZeneca Pharmaceuticals, LP
2021 - 2025
-
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
awarded by Suzhou Zanrong Pharma Limited
2020 - 2025
-
ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets
awarded by Department of Defense
2022 - 2024
-
ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets
awarded by Department of Defense
2022 - 2024
-
R01 Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
awarded by National Institutes of Health
2020 - 2024
-
A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
awarded by Angiochem Inc.
2019 - 2024
-
Retrospective tissue study HER2-positive breast cancer prediction of brain metastasis
awarded by Caris Life Sciences
2021 - 2023
-
Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model
awarded by University of Tennessee Health Science Center
2022 - 2023
-
Ancestry-related RNA splicing and immune expression in metastatic breast cancer
awarded by Susan G. Komen Breast Cancer Foundation
2022
-
Dr. Anders-Cancer Research
awarded by 5 for the Fight
2022
-
T32 UNC - Duke Immunotherapy Training Program
awarded by University of North Carolina - Chapel Hill
2021 - 2022
-
Discovery and validation of putative oncogenic ROS1 alterations in metastatic breast cancer
awarded by Metavivor
2020 - 2022
-
Immunotherapy to treat Triple Negative Breast Cancer Brain Metastases
awarded by University of North Carolina - Chapel Hill
2019 - 2021
-
In Vitro Fertilization Outcomes in Women Diagnosed with Cancer
awarded by University of North Carolina - Chapel Hill
2020 - 2021
-
Molecular Dissection and Immune Characterization of Breast Cancer Brain Metastases to Predict Outcomes and Reveal Novel Therapeutic Strategies
awarded by Conquer Cancer Foundation
2019
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.